Article date: July 2005
By: Florent Puisset, Florence Dalenc, Etienne Chatelut, Thierry Cresteil, Isabelle Lochon, Pierre Tisnes, Henri Roché, in Volume 60, Issue 1, pages 45-53
Aim
To assess the value of using dexamethasone as an in vivo probe for predicting vinorelbine clearance (CL).
Methods
A population approach (implemented with NONMEM) was used to analyse blood vinorelbine pharmacokinetic data from 20 patients who received a 20‐min intravenous infusion of vinorelbine (from 20 to 30 mg m−2). Selected patient clinical data as well as known functional single CYP3A5 and ABCB1 genotype were also tested as covariates.
Results
The best covariate model (with ± 95% confidence intervals) was based on dexamethasone plasma clearance (DPC) and alkaline phosphatase (ALP): vinorelbine blood CL (l h−1) = 39.8(± 4.0) × (DPC/13.2)0.524(±0.322) × (ALP/137)−0.198(±0.158). Interindividual variability in vinorelbine CL decreased from 29.7% (model without covariate) to 14.7% when including DPC and ALP. Vinorelbine CL was not correlated with body surface area (BSA) or associated with CYP3A5 and ABCB1 genotype.
Conclusions
These results indicate that individualization of vinorelbine dose would be improved by using dexamethasone clearance rather than BSA. Dexamethasone merits further evaluation as a probe of CYP3A metabolism.
DOI: 10.1111/j.1365-2125.2005.02384.x
View this article